Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy ; volume:8 ; number:1 ; day:11 ; month:12 ; year:2023 ; pages:1-2 ; date:12.2023
Signal transduction and targeted therapy ; 8, Heft 1 (11.12.2023), 1-2, 12.2023
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-023-01696-x
- URN
-
urn:nbn:de:101:1-2024022307543601405785
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brichkina, Anna
- Suezov, Roman
- Huber, Magdalena
- SpringerLink (Online service)
Other Objects (12)
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Minimal change disease associated with anti-PD1 immunotherapy: a case report
PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation
Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Minimal change disease associated with anti-PD1 immunotherapy: a case report
PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation
Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Minimal change disease associated with anti-PD1 immunotherapy: a case report
PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation
Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target